6269-25-6

Basic information

• Product Name: 2-(HYDROXYMETHYL)-5-METHOXY-4H-PYRAN-4-ONE
• Synonyms: 2-(HYDROXYMETHYL)-5-METHOXY-4H-PYRAN-4-ONE;2-(hydroxymethyl)-5-methoxy-4-pyranone;2-(hydroxymethyl)-5-methoxy-pyran-4-one;2-(hydroxymethyl)-5-methoxypyran-4-one;4H-Pyran-4-one, 2-(hydroxymethyl)-5-methoxy-;5-methoxy-2-methylol-pyran-4-one
• CAS NO: 6269-25-6
• Molecular Formula: C₇H₈O₄
• Molecular Weight: 156.14
• Mol File: 6269-25-6.mol
• Article Data: 21

Chemical Properties

• Melting Point: 165-167°
• Boiling Point: 381.3 °C at 760 mmHg
• Flash Point: 165.6 °C
• Appearance: /
• Density: 1.3 g/cm³
• Vapor Pressure: 2.22E-07mmHg at 25°C
• Refractive Index: 1.529
• PKA: 14.83±0.10(Predicted)
• CAS DataBase Reference: 2-(HYDROXYMETHYL)-5-METHOXY-4H-PYRAN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(HYDROXYMETHYL)-5-METHOXY-4H-PYRAN-4-ONE(6269-25-6)
• EPA Substance Registry System: 2-(HYDROXYMETHYL)-5-METHOXY-4H-PYRAN-4-ONE(6269-25-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 6269-25-6(Hazardous Substances Data)

Usage

Uses

2-(Hydroxymethyl)-5-methoxy-4H-pyran-4-one is a research chemical used in the assessment of it’s inhibition of HIV-1.

InChI:InChI=1/C7H8O4/c1-10-7-4-11-5(3-8)2-6(7)9/h2,4,8H,3H2,1H3

Upstream product

• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 77-78-1 dimethyl sulfate 
• 74-83-9 methyl bromide 
• 74-88-4 methyl iodide 
• 40838-34-4 2-chloromethyl-5-methoxy-4H-pyran-4-one 
• 186581-53-3 diazomethane 

Downstream Products

• 62885-42-1 4-Hydroxy-2-hydroxymethyl-5-methoxypyridin 
• 6266-91-7 5-methoxy-2-methyl-4H-pyran-4-one 
• 1091682-22-2 (1-{(S)-2-[(R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethyl-butyryl}-piperidin-4-yl)-(5-methoxy-4-oxo-4H-pyran-2-ylmethyl)-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1091682-24-4 (R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-N-((S)-1-{4-[(5-methoxy-4-oxo-4H-pyran-2-ylmethyl)-amino]-piperidine-1-carbonyl}-2,2-dimethyl-propyl)-propionamide 
• 103878-33-7 4-chloro-5-methoxypicolinic acid 
• 857433-67-1 methyl 4-chloro-5-methoxypyridine-2-carboxylate 
• 51727-04-9 4-Hydroxy-5-methoxypyridin-2-carbonsaeure 
• 50700-60-2 3-methoxy-4(1H)-pyridone 
• 1193-64-2 3-methoxy-4H-pyran-4-one 
• 1609394-90-2 (E)-2-(4-(dimethylamino)styryl)-5-methoxy-4H-pyran-4-one 
• 1609394-89-9 (E)-5-methoxy-2-(4-(trifluoromethoxy)styryl)-4H-pyran-4-one 
• 1609394-88-8 (E)-5-methoxy-2-(4-(trifluoromethyl)styryl)-4H-pyran-4-one 
• 1609394-86-6 (E)-2-(3,4,5-trimethoxystyryl)-5-methoxy-4H-pyran-4-one 
• 1609394-85-5 (E)-2-(3,5-dimethoxystyryl)-5-methoxy-4H-pyran-4-one 

Relevant articles and documents

-

-

NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed are a novel isoindoline derivative, a pharmaceutical composition and use thereof. The compound of formula I, or the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof disclosed in the invention can regulate the generation and/or activity of PDE4 and/or TNF-α so as to effectively treat cancer and inflammatory diseases.

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

Kojic gallate compounds and application thereof as tyrosinase inhibitor

The invention relates to synthesis of kojic gallate compounds in a formula (I) and an application of the compounds in inhibiting tyrosinase. Screening results of in-vitro inhibition of tyrosinase showthat kojic gallate has higher tyrosinase inhibiting activity and is superior to positive control, namely, kojic acid. The compounds have novel structure, are simple to prepare and have broad application prospects in the field of medicines, cosmetics and food preservation. The chemical structural formula of the kojic gallate compounds is shown in the description, wherein R is hydrogen, methyl andbenzyl.